Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.

Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, Jackson SS, Gorgone DA, Lifton MA, Essex M, Walker BD, Goudsmit J, Havenga MJ, Barouch DH.

J Immunol. 2005 Jun 1;174(11):7179-85.

2.

Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.

Bradley RR, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH.

J Virol. 2012 Jan;86(1):625-9. doi: 10.1128/JVI.06254-11. Epub 2011 Nov 9.

3.

Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.

Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA, Lifton MA, Koudstaal W, Pau MG, Kostense S, Havenga MJ, Goudsmit J, Letvin NL, Barouch DH.

J Virol. 2004 Mar;78(6):2666-73.

4.

Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.

Bradley RR, Maxfield LF, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH.

J Virol. 2012 Jan;86(2):1267-72. doi: 10.1128/JVI.06165-11. Epub 2011 Nov 9.

5.

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH.

Nature. 2006 May 11;441(7090):239-43. Epub 2006 Apr 16.

PMID:
16625206
6.

Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.

Bruder JT, Semenova E, Chen P, Limbach K, Patterson NB, Stefaniak ME, Konovalova S, Thomas C, Hamilton M, King CR, Richie TL, Doolan DL.

PLoS One. 2012;7(4):e33920. doi: 10.1371/journal.pone.0033920. Epub 2012 Apr 5. Erratum in: PLoS One. 2012;7(5): doi/10.1371/annotation/c110beed-3cac-48db-9039-ba4498d5db50.

7.

Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon.

Tian X, Su X, Li H, Li X, Zhou Z, Liu W, Zhou R.

Virus Res. 2011 Sep;160(1-2):214-20. doi: 10.1016/j.virusres.2011.06.017. Epub 2011 Jun 29.

PMID:
21740937
8.

Construction and characterization of a recombinant human adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon.

Xue C, Tian X, Li X, Zhou Z, Su X, Zhou R.

Virus Res. 2014 Apr;183:67-74. doi: 10.1016/j.virusres.2014.01.027. Epub 2014 Feb 8.

PMID:
24518297
9.

Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions.

Qiu H, Li X, Tian X, Zhou Z, Xing K, Li H, Tang N, Liu W, Bai P, Zhou R.

J Virol. 2012 Aug;86(15):7964-75. doi: 10.1128/JVI.07076-11. Epub 2012 May 23.

10.

First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).

Baden LR, Walsh SR, Seaman MS, Johnson JA, Tucker RP, Kleinjan JA, Gothing JA, Engelson BA, Carey BR, Oza A, Bajimaya S, Peter L, Bleckwehl C, Abbink P, Pau MG, Weijtens M, Kunchai M, Swann EM, Wolff M, Dolin R, Barouch DH.

J Infect Dis. 2014 Oct 1;210(7):1052-61. doi: 10.1093/infdis/jiu217. Epub 2014 Apr 8.

11.

Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.

Bruder JT, Chen P, Semenova E, Thomas CA, Konovalova S, Ekberg G, Ettyreddy D, McVey D, Gall JG, King CR, Brough DE.

J Virol. 2013 Sep;87(17):9661-71. doi: 10.1128/JVI.00462-13. Epub 2013 Jul 3.

12.

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J.

J Immunol. 2004 May 15;172(10):6290-7.

13.

Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector.

Myhre S, Henning P, Granio O, Tylö AS, Nygren PA, Olofsson S, Boulanger P, Lindholm L, Hong SS.

Gene Ther. 2007 Feb;14(4):376-81. Epub 2006 Oct 12.

PMID:
17036056
14.

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, Goudsmit J, Havenga MJ, Barouch DH.

J Virol. 2005 Aug;79(15):9694-701.

15.

Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.

Wu WH, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA.

Virol J. 2015 Sep 11;12:140. doi: 10.1186/s12985-015-0364-7.

16.

Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.

Ura T, Yoshida A, Xin KQ, Yoshizaki S, Yashima S, Abe S, Mizuguchi H, Okuda K.

J Gene Med. 2009 Feb;11(2):139-49. doi: 10.1002/jgm.1277.

PMID:
19065543
17.

Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.

Thorner AR, Lemckert AA, Goudsmit J, Lynch DM, Ewald BA, Denholtz M, Havenga MJ, Barouch DH.

J Virol. 2006 Dec;80(24):12009-16. Epub 2006 Oct 11.

18.

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.

Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P, Sinangil F, de Bruyn G, Gray GE, Roux S, Bekker LG, Dilraj A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amornkul PN, Gilmour J, Hural J, Buchbinder SP, Seaman MS, Dolin R, Baden LR, Carville A, Mansfield KG, Pau MG, Goudsmit J.

Vaccine. 2011 Jul 18;29(32):5203-9. doi: 10.1016/j.vaccine.2011.05.025. Epub 2011 May 25.

19.

Interaction between hexon and L4-100K determines virus rescue and growth of hexon-chimeric recombinant Ad5 vectors.

Yan J, Dong J, Wu J, Zhu R, Wang Z, Wang B, Wang L, Wang Z, Zhang H, Wu H, Yu B, Kong W, Yu X.

Sci Rep. 2016 Mar 3;6:22464. doi: 10.1038/srep22464.

20.

Characteristics of neutralizing antibodies to adenovirus capsid proteins in human and animal sera.

Yu B, Dong J, Wang C, Zhan Y, Zhang H, Wu J, Kong W, Yu X.

Virology. 2013 Mar 15;437(2):118-23. doi: 10.1016/j.virol.2012.12.014. Epub 2013 Jan 23.

Supplemental Content

Support Center